| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 |
| filingDate |
2018-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020532559-A |
| titleOfInvention |
Co-crystal of orally administrable HIF prolyl hydroxylase inhibitor |
| abstract |
The present invention relates to a co-crystal of Lokidustat with L-proline and a method for producing the same. Furthermore, the present invention relates to a pharmaceutical composition comprising said Loxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient, and optionally at least one light stabilizer. The pharmaceutical composition of the present invention can be used as a medicine, especially for the treatment and / or prevention of anemia in patients with end-stage renal disease (ESRD) and / or chronic renal disease (CKD). |
| priorityDate |
2017-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |